Compare Ascendis Pharma A/S (ASND) vs Progressive Corp (PGR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Progressive Corp — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Progressive Corp trades at $231.02 (market cap $134.33B). The key difference: Progressive Corp is far larger — about 7.6× Ascendis Pharma A/S's market cap, and Progressive Corp pays a 6.02% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | PGR | |
|---|---|---|
Market Cap | $17.74B | $134.33B |
Sector | Health | Financials |
52-Week High | $277.18 | $252.68 |
52-Week Low | $163.32 | $190.40 |
Enterprise Value | $18.11B | $142.55B |
Dividend Yield | — | 6.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Progressive (PGR) trades at $230.72, up 0.52% on the day, with a bullish technical outlook indicated by moving averages and strong support at $228. The stock shows robust fundamentals with revenue growing from $49.6B in 2022 to $87.6B in 2025 and net income surging to $11.3B. Recent earnings beats and a 36% jump in May 2026 net income highlight operational strength. The company maintains a solid net income margin of 12.93% and an impressive ROE of 37.9%.
The outlook for PGR is positive, supported by consistent earnings outperformance and analyst consensus pointing to upside with a $239.75 price target. Key risks include competitive pressures in the insurance sector and potential macroeconomic headwinds affecting consumer spending. Institutional sentiment is mixed but leans bullish, with 39% of analysts rating it a buy. The stock presents a compelling opportunity for growth investors seeking exposure to a financially healthy insurer.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →
